Recent modalities in treatment of telogen effluvium: Comparative study.
botulinum toxin A
mesotherapy
telogen effluvium
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
09
06
2022
accepted:
04
07
2022
pubmed:
20
7
2022
medline:
5
10
2022
entrez:
19
7
2022
Statut:
ppublish
Résumé
Telogen effluvium is one of the most common forms of diffuse, non-scarring hair loss for which patients present for clinical evaluation. It is usually a reactive and reversible disorder. Identifying and correcting the underlying cause is the most important component in management, yet there is always a need for therapeutic options. This study aims to evaluate the efficacy of single session botulinum toxin A injection versus multiple sessions of multivitamins mesotherapy in the treatment of telogen effluvium. A randomized clinical trial was conducted in the Dermatology, Venereology, and Andrology Department, Faculty of Medicine, Zagazig University Hospitals. Twenty-four patients with telogen effluvium were randomly divided into two groups each group included 12 patients. Group I received a single session of Botulinum toxin A injection and group II received multiple sessions of multivitamins mesotherapy injection. Both botulinum toxin A and multivitamins mesotherapy are effective in the treatment of telogen effluvium, which was reflected on the improvement of hair parameters as terminal hair and multiple follicular units. Both treatment modalities had minimal and well-tolerated side effects. Although both therapies have equivalent success rates, single session of botulinum toxin A is a better choice than multiple mesotherapy sessions.
Substances chimiques
Botulinum Toxins, Type A
EC 3.4.24.69
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15720Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Malkud S. Telogen effluvium: a review. J Clin Diagn Res. 2015;9:WE01-WE03.
Harrison S, Bergfeld W. Diffuse hair loss: its triggers and management. Cleve Clin J Med. 2009;76(6):361-367.
Mysore V. Mesotherapy in management of hairloss-is it of any use? Int J Trichol. 2010;2:45-46.
Atiyeh BS, Ibrahim AE, Dibo SA. Cosmetic mesotherapy: between scientific evidence, science fiction, and lucrative business. Aesthetic Plast Surg. 2008;32(6):842-849.
Nassar A, Abdel-Aleem H, Samir M, Khattab FM. Efficacy of botulinum toxin a injection in the treatment of androgenic alopecia: a comparative controlled study. J. Cosmetic Dermatol. 2022;8:15-28. doi:10.1111/jocd.14817
Sehdev S, Shekhar N, Biju V. A pilot study to evaluate effectiveness of botulinum toxin in treatment of androgenetic Alopecia. Males J Cutan Aesthet Surg. 2017;10(3):163-167.
Nilam J, Bhavana D, Uday K. Trichoscopy in alopecias: diagnosis simplified. Int J Trichol. 2013;5(4):170-178.
Mesotherapy VM. Mesotherapy. Indian J Dermatol Venereol Leprol. 2007;73(1):60-62.
Olsen EA. Current and novel methods for assessing efficacy of hair growth promoters in pattern hair loss. J Am Acad Dermatol. 2003;48(2):253-262.
Gaurrera M. Additional methods for diagnosing alopecia and appraising their severity. G Ital Dermatol Venereol. 2014;149(1):93-102.
Rallis E, Kintzoglou S, Moussatou V, Riga P. Mesotherapy-induced urticaria. Dermatol Surg. 2010;36(8):1355-1356.
Harrison S, Sinclair R. Telogen effluvium. Clin Exp Dermatol. 2002;27(5):389-395.
Rebora A. Proposing a simpler classification of telogen effluvium. Skin Appendage Disord. 2016;2(1-2):35-38.
Rebora A, Guarrera M, Drago F. Postpartum telogen effluvium. J Eur Acad Dermatol Venereol. 2016;30(3):518.
Shon U, Kim MH, Lee DY, Kim SH, et al. The effect of intradermal botulinum toxin on androgenetic alopecia and its possible mechanism. JAAD. 2020;83(6):1838-1839.
Zhou Y, Yu S, Zhao J, Feng X, Zhang M, Zhao Z. Effectivness and safety of botulinum toxin type a in the treatment of androgenetic alopecia. Biomed Res Int. 2020;2020:1501893.